Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...
That’s according to the Deloitte U.S. Center for Health Solutions, which found in a recent survey of 150 C-suite executives ...
The second and more recent probe involves alleged smuggling of unapproved drugs—the Daiichi-partnered HER2 therapy Enhertu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback